Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 74Kidney Neoplasms 27Prostatic Neoplasms 16Neoplasm Metastasis 11Urinary Bladder Neoplasms 5Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Neuroendocrine Tumors 3Carcinoma, Transitional Cell 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Margins of Excision 2Insulinoma 2Glucagonoma 2Gastrinoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Islet Cell 2Urothelial Cancer 1Ureteral Neoplasms 1Tuberous Sclerosis 1Thrombocytosis 1Testicular Neoplasms 1Renal Cell Cancer Metastatic 1Prostate Cancer Patients With Detectable PSA Following Prostatectomy 1Primary Myelofibrosis 1

Interventions

Docetaxel 4radium Ra 223 dichloride 2Prednisone 2sargramostim 1gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1PE regimen 1Mycobacterium w vaccine 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Denosumab 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Refractory Prostate Cancer × Everolimus × Genitourinary × Clear all
NCT00629525 2015-03-03

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Duke University

Phase 2 Completed
35 enrolled 6 charts
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡